These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. van Erp EA; van Kasteren PB; Guichelaar T; Ahout IML; de Haan CAM; Luytjes W; Ferwerda G; Wicht O J Virol; 2017 Nov; 91(21):. PubMed ID: 28794038 [TBL] [Abstract][Full Text] [Related]
12. Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4. Barban V; Mantel N; De Montfort A; Pagnon A; Pradezynski F; Lang J; Boudet F J Virol; 2018 Jun; 92(12):. PubMed ID: 29593041 [TBL] [Abstract][Full Text] [Related]
13. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens. Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114 [TBL] [Abstract][Full Text] [Related]
15. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity. Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880 [TBL] [Abstract][Full Text] [Related]
16. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone. Osorio JE; Wallace D; Stinchcomb DT Expert Rev Vaccines; 2016; 15(4):497-508. PubMed ID: 26635182 [TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study. Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225 [TBL] [Abstract][Full Text] [Related]
18. Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development. Acosta EG; Bartenschlager R Expert Rev Vaccines; 2016; 15(4):467-82. PubMed ID: 26577689 [TBL] [Abstract][Full Text] [Related]
19. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. Whitehead SS; Durbin AP; Pierce KK; Elwood D; McElvany BD; Fraser EA; Carmolli MP; Tibery CM; Hynes NA; Jo M; Lovchik JM; Larsson CJ; Doty EA; Dickson DM; Luke CJ; Subbarao K; Diehl SA; Kirkpatrick BD PLoS Negl Trop Dis; 2017 May; 11(5):e0005584. PubMed ID: 28481883 [TBL] [Abstract][Full Text] [Related]
20. Generation and preclinical evaluation of a DENV-1/2 prM+E chimeric live attenuated vaccine candidate with enhanced prM cleavage. Keelapang P; Nitatpattana N; Suphatrakul A; Punyahathaikul S; Sriburi R; Pulmanausahakul R; Pichyangkul S; Malasit P; Yoksan S; Sittisombut N Vaccine; 2013 Oct; 31(44):5134-40. PubMed ID: 23973247 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]